Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;70(4):851-861.
doi: 10.1002/mus.28227. Epub 2024 Aug 8.

Visualization and characterization of complement activation in acetylcholine receptor antibody seropositive myasthenia gravis

Yu-Fang Huang  1 , Kerstin Sandholm  2 , Barbro Persson  3 , Bo Nilsson  3 , Anna Rostedt Punga  1
Affiliations

Visualization and characterization of complement activation in acetylcholine receptor antibody seropositive myasthenia gravis

Yu-Fang Huang et al. Muscle Nerve. 2024 Oct.

Abstract

Introduction/aims: There are no blood biomarkers to monitor treatment effects in myasthenia gravis (MG) or studies visualizing the acetylcholine receptor (AChR) antibody-induced membrane attack complex (MAC) at the human muscle membrane. This study aimed to compare levels of complement activation products and native complement components in MG patients and healthy controls (HCs) and to model the AChR antibody-mediated attacks in human muscle cells.

Methods: We assessed the complement components and activation product levels with enzyme-linked immunosorbent assay and magnetic bead-based sandwich assays in plasma and sera of 23 MG patients and matched HCs. Receiver operator characteristic (ROC) curve analysis evaluated the diagnostic accuracy. Complement levels were correlated with the myasthenia gravis composite (MGC) scores. AChR+ MG modeling in human muscle cells used sera from nine MG patients and three HCs.

Results: MG patients had significantly higher plasma levels of C3a (p < .0001), C5 (p = .0003), and soluble C5b-9 (sC5b-9; p < .0001) than HCs. The ROC curve analysis showed a clear separation between MG patients and HCs for plasma C3a (AUC = 0.9720; p < .0001) and sC5b-9 (AUC = 0.8917, p < .0001). MG patients had higher levels of plasma complement Factor I (FI; p = .0002) and lower properdin levels (p < .0001). The MGC had moderate correlations with plasma Factor B (FB), FI, and Factor H. AChR+ MG patient sera triggered the deposition of MAC and reduced AChRs.

Discussion: We suggest validating plasma C3a and sC5b-9 as blood biomarkers for complement activation in MG. Further, the in vitro study allowed visualization of MAC deposition after applying AChR+ MG sera on human muscle cells.

Keywords: MGC; biomarker; complement; membrane attack complex; myasthenia gravis.

PubMed Disclaimer

References

REFERENCES

    1. Conti‐Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116(11):2843‐2854.
    1. Strauss AJL, Seegal BC, Hsu KC, Burkholder PM, Nastuk WL, Osserman KE. Immunofluorescence demonstration of a muscle binding, complement‐fixing serum globulin fraction in myasthenia gravis. Proc Soc Exp Biol Med. 1960;105(1):184‐191.
    1. Engel AG, Lambert EH, Howard FM. Immune complexes (IgG and C3) at the motor end‐plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc. 1977;52(5):267‐280.
    1. Engel AG, Sakakibara H, Sahashi K, Lindstrom JM, Lambert EH, Lennon VA. Passively transferred experimental autoimmune myasthenia gravis. Sequential and quantitative study of the motor end‐plate fine structure and ultrastructural localization of immune complexes (IgG and C3), and of the acetylcholine receptor. Neurology. 1979;29(2):179‐188.
    1. Nakano S, Engel AG. Myasthenia‐gravis—quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end‐plate in 30 patients. Neurology. 1993;43(6):1167‐1172.

Substances

LinkOut - more resources